Edwards Lifesciences (EW) FY2025 Earnings Quality Report

Grade: C — Some Red Flags, Investigate

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-25) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (1 critical audit matter: uncertain tax positions related to intercompany transfer pricing)

One-line verdict: Edwards Lifesciences earns a C driven by a single mechanical fail — FY2024 free cash flow collapsed to $0.26B on a net income base of $4.17B, tripping the two-year FCF screen even though FY2025 FCF recovered to $1.33B. Strip away the one-time BD divestiture distortion and the underlying business is clean: 17/18 checks pass, M-Score is -2.62 (deep in the safe zone), cash of $4.2B towers over $0.7B of debt, and gross margin sits at 78.0%. The C grade is a technical artifact of a lumpy cash flow year, not a warning about earnings quality.

The Structural Heart Pure-Play

Edwards is, in its own words, "the leading global structural heart innovation company." From the 10-K: "We are the leading global structural heart disease innovation company, driven by a passion to improve patient lives."

In FY2025 the company reported $6.07B in net sales, up 11.5% from $5.44B in FY2024. The 10-K provides a clean product breakdown:

TAVR remains the dominant franchise. The 10-K explains: "Sales of our TAVR products represented 74%, 75%, and 77% of our net sales in 2025, 2024, and 2023, respectively." The flagship SAPIEN 3 Ultra RESILIA drove the US and European growth, while PASCAL and EVOQUE powered the 56% jump in TMTT.

The portfolio change matters for comparability. On September 3, 2024, Edwards sold its Critical Care product group to Becton, Dickinson (BD). On December 18, 2025, it divested a non-core product group. From the 10-K: "the historical financial condition and results of the discontinued product groups have been reflected as discontinued operations in our consolidated financial statements. Our discussion and analysis of our results of operations is reflective of our continuing operations."

The $4.17B FY2024 net income reflects the gain on sale of Critical Care to BD — a non-recurring, non-operating event. FY2025 net income of $1.07B is a more representative ongoing figure. The 10-K explains: "The decrease in our net income and diluted earnings per share in 2025 was driven primarily by increases in personnel-related costs, one-time charges related to impairments on our investments, and increased certain litigation expenses."

Cash Flow: Normalizing After a Lumpy FY2024

The FY2024 collapse in CFFO to $0.54B — against net income of $4.17B — is the cause of the single failing check. The divestiture created a large non-cash gain that inflated GAAP net income while cash from operations actually fell. FY2025 saw the normalization: CFFO recovered to $1.60B, up 194%.

From the 10-K: "As of December 31, 2025, cash, cash equivalents, and short-term investments held in the United States and outside of the United States were $3.7 billion and $516.1 million, respectively."

Edwards runs with a fortress balance sheet: $4.2B in cash and short-term investments against just $0.7B in total debt. The 10-K discloses: "We have a five-year Credit Agreement (the Credit Agreement) that provides for a $750.0 million multi-currency unsecured revolving credit facility and matures on July 15, 2027."

The 18-Point Screening

Revenue Quality

All three revenue-quality checks pass cleanly. Accounts receivable of $0.66B on $6.07B revenue produces a DSO of just 40 days — excellent working capital discipline for a device maker. Cash collections grew nearly 20x faster than revenue in FY2025, reflecting the normalization from FY2024.

Expense Quality

Inventory growth of 3.6% versus COGS growth of 19.4% indicates tight inventory control. Gross margin at 78.0% is industry-leading for medical devices. The small 1.4pp margin decline aligns with management's own explanation that "Gross profit as a percentage of sales decreased primarily due to higher operational expenses."

Cash Flow Quality

C2 is the lone failing check. The engine flags that FCF was less than 50% of net income in FY2023 ($0.63B vs $1.40B = 45%) and especially in FY2024 ($0.26B vs $4.17B = 6%). However, the FY2024 figure is mechanically distorted: the $4.17B denominator includes the gain on the Critical Care divestiture, which is non-cash on the operating line. Strip out the gain and the ratio normalizes. FY2025 FCF/NI recovered to 1.24 — well above the threshold.

Balance Sheet

Debt/EBITDA of 0.5x is among the lowest in the medical device sector. Goodwill and intangibles totaling $2.9B represent just 28% of the $10.3B equity base — well below the 30% watch threshold. Edwards is debt-averse by design.

M&A Risk

Beneish M-Score

M-Score of -2.62 sits comfortably below the -2.22 threshold.

Key Risks from Item 1A

From the 10-K: "Our business and assets are subject to varying degrees of risk and uncertainty." Edwards organizes the risk factors into Business and Operating, Global Macroeconomic, and Legal/Compliance buckets.

1. Failure to innovate and develop differentiated products. The first-listed risk factor: "Our continued growth and success depend on our ability to innovate and develop new and differentiated products in a timely manner and effectively market these products. Without timely innovation and development, our products could be rendered obsolete or less competitive because of the introduction of a competitor's newer technologies or changing customer preferences." The 10-K goes further: even with successful innovation, marketing success depends on "competitive products and pricing, barriers in patient activation (including disease awareness, detection, and diagnosis), restrictive requirements in the U.S. national coverage determination for transcatheter aortic valve replacement procedures, the need for regulatory clearance...capacity constraints within hospital systems, including staffing shortages and the availability of catheterization laboratories, and uncertainty over third-party reimbursement."

2. Competition from Medtronic and Abbott. The 10-K is explicit about who competes against Edwards: "In TAVR, our primary competitors include Medtronic plc (Medtronic) and Abbott Laboratories (Abbott). In TMTT, our primary competitor is Abbott, and there are a considerable number of large and small companies with development efforts in these fields. In Surgical, our primary competitors include Medtronic and Abbott." This is a concentrated-competition market where any product setback at Edwards directly benefits two well-capitalized rivals.

3. Reimbursement and government pricing pressure. From the 10-K summary: "Inability to obtain government reimbursement or reductions in reimbursement levels." TAVR in particular depends on favorable national coverage determinations and hospital reimbursement rates.

4. Uncertain tax positions — the critical audit matter. From the 10-K: "The Company had an uncertain gross tax positions balance of $767.4 million as of December 31, 2025, of which a majority is related to intercompany transfer pricing." PwC flagged this as the sole critical audit matter because "Significant judgment is required by management in evaluating uncertain tax positions, including estimating the ultimate resolution to intercompany pricing controversies between countries when there are numerous possible outcomes."

5. Clinical trial and regulatory risk. "Unsuccessful clinical trials or procedures" appears as a distinct risk factor — highly relevant given Edwards' active pipeline including the CLASP IIF trial for PASCAL and the ENCIRCLE pivotal trial for mitral and tricuspid therapies.

Altman Z-Score and F-Score

The Altman Z of 9.61 places Edwards among the safest balance sheets in healthcare. The F-Score of 0.51 (probability 0.19%) signals low risk of material misstatement.

Summary

Grade: C. Seventeen checks pass; the one failure is a mechanical artifact of the Critical Care divestiture gain distorting FY2024 net income.

Edwards Lifesciences runs one of the cleanest operating profiles in medical devices: 78% gross margins, $4.2B in cash against $0.7B of debt, and a focused TAVR/TMTT/Surgical portfolio. The single failing check (C2: FCF < 50% of NI for two years) directly traces to the BD sale accounting. FY2025 FCF of $1.33B against $1.07B of net income produces an FCF/NI ratio of 1.24 — comfortably above the 50% threshold. Every other metric — DSO, inventory discipline, accruals, leverage, goodwill, M-Score, Z-Score — clears its bar without drama.

The real risks, as Item 1A makes clear, are operational rather than financial: sustaining product innovation against Medtronic and Abbott, managing reimbursement dynamics, and navigating the transfer-pricing audit matter. The balance sheet is built to absorb any of those stresses comfortably.

**Disclaimer**: This report is based on Edwards Lifesciences' FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2026-02-25) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 1 critical audit matter)